Heart Drugs News: September 2006 Archives

Bayer says mistakenly failed to disclose drug data


German drug maker Bayer AG "mistakenly" failed to inform U.S. regulators about a study on the risks of heart-surgery drug Trasylol before an advisory panel met and ruled the side effects were acceptable, the company said on Friday.

Bayer believes that despite the highly preliminary nature of this data, the information should have been shared with the FDA prior to the September 21 advisory committee meeting ... This was a mistake on the company's part

Heart database aims to spot drug side effects


More than 200,000 heart tests from patients in prescription drug trials will be collected in a database so scientists can search for clues about potentially dangerous cardiac side effects, U.S. health officials said on Wednesday.